Cibus (CBUS) Income from Continuing Operations (2016 - 2026)
Cibus (CBUS) posted Income from Continuing Operations of 31948000.0 for Q4 2025, down 31.46% sequentially from 24303000.0 in Q3 2025, and down 23.81% YoY from 41932156.26 in Q4 2024.
Cibus (CBUS) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Cibus has reported Income from Continuing Operations for 10 years, with the latest figure at 31948000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 23.81% year-over-year to 31948000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 132201000.0 (up 53.24% YoY) and the FY2025 annual result came in at 132201000.0, up 53.24% from the prior year.
- Income from Continuing Operations declined to 31948000.0 in Q4 2025 per CBUS's latest filing, from 24303000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2485000.0 in Q2 2022 and troughed at 277208000.0 in Q4 2023.
- A 5-year average of 39932150.0 and a median of 22406000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 9671.17% in 2023, then soared 90.69% in 2024.
- Over 5 years, Income from Continuing Operations stood at 7057000.0 in 2021, then soared by 59.8% to 2837000.0 in 2022, then slumped by 9671.17% to 277208000.0 in 2023, then jumped by 90.69% to 25804000.0 in 2024, then declined by 23.81% to 31948000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 31948000.0, 24303000.0, and 26558000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | -22.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.15 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -24.30 Mn |
| Jun 30, 2025 | -26.56 Mn |
| Mar 31, 2025 | -49.39 Mn |
| Dec 31, 2024 | -25.80 Mn |
| Sep 30, 2024 | -201.46 Mn |
| Jun 30, 2024 | -28.48 Mn |
| Mar 31, 2024 | -26.97 Mn |
| Dec 31, 2023 | -277.21 Mn |
| Sep 30, 2023 | -34.53 Mn |
| Jun 30, 2023 | -20.51 Mn |
| Mar 31, 2023 | -5.39 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -5.95 Mn |
| Jun 30, 2022 | -2.49 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -7.31 Mn |
| Jun 30, 2021 | -4.81 Mn |